

Announcement of business alliance (MR activities /medical information support)

LTL Pharma Co., Ltd. (Head office: Tokyo, chairman and representative director: Sansei Oka, president and representative director: Jiro Mizukawa) and OrphanPacific, Inc. (Head office: Tokyo, president and representative director: Philippe Auvaro) are pleased to announce that they entered into a business alliance agreement. Through this partnership, LTL Pharma will be responsible for the manufacture and sale of long-listed-drugs transferred from Astellas Pharma Inc. While OrphanPacific will supervise the medical representatives (MR) activity including information provision and collection of products through visits to medical institutions in full compliance with Good Pharmacovigilance Practices (GVP)

LTL Pharma is a pharmaceutical company relying upon experts from various fields, and was considering about outsourcing of MR activities and support in medical information. Meanwhile, OrphanPacific has previously gained experience in the transfer of marketing authorization of long-listed-drugs and the flexibility demonstrated in this partnership confirmed the intentions of both companies to reach an agreement for an alliance.

About LTL Pharma

<https://www.ltl-pharma.com>

LTL Pharma Co., Ltd. is a subsidiary of Japan Established Medicine Corporation (Head office: Tokyo). LTL Pharma handles long-listed-drugs that have been prescribed for many years by many medical institutions. Together with long-listed-drugs, accumulated data concerning quality, efficacy and safety, LTL Pharma strives to ensure stable supply of products that maintain original product reliability.

LTL Pharma will contribute to the health of the patients as well as continue to maintain quality, ensure stable supply, and collect and provide safety information so that we can respond to the needs of patients who are taking the same medication over several years, and medical specialists who are familiar with the efficacy and the safety of these drugs.

About OrphanPacific

<https://www.orphanpacific.com/en/>

OrphanPacific established in 2012 as a joint venture between CMIC Holdings, which owns the largest CRO in Japan, and MEDIPAL Holdings, the largest pharmaceutical wholesaler in Japan, with the aim to create a new business model for medical drugs centered on rare diseases (orphan drugs) to the Japanese healthcare professionals and their patients. OrphanPacific is committed to ensure stable supply of quality essential drugs and to introduce rare disease treatments to Japanese patients. Orphan Drugs strategy mainly relies upon the support extended to overseas bio-pharmaceutical companies that have no presence in Japan in order to assist their Japanese market entry strategy by leveraging CMIC domestic and overseas networks.

Inquiries concerning this announcement

LTL Pharma Co., Ltd.

LTL Pharma Call Center

TEL:0120-303-711

Monday to Friday 9:00 a.m. to 5:30 p.m. on weekdays

<https://www.ltl-pharma.com/contact/>

OrphanPacific Inc.

OrphanPacific Call Center

TEL:0120-889-009

Monday to Friday 9:00 a.m. to 5:30 p.m. on weekdays

<https://www.orphanpacific.com/en/contact/>